Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers

被引:87
|
作者
Temraz, Sally [1 ]
Mukherji, Deborah [1 ]
Shamseddine, Ali [1 ]
机构
[1] Amer Univ Beirut, Med Ctr, Div Hematol Oncol, Dept Internal Med, Beirut 110 72020, Lebanon
来源
关键词
colorectal cancer; drug resistance; phosphatidylinositol; 3-kinase; mitogen-activated protein kinase; MEK; TUMOR-GROWTH; AZD6244; ARRY-142886; PHASE-I; SELUMETINIB AZD6244; KINASE INHIBITORS; PIK3CA MUTATION; K-RAS; COMBINATION; RESISTANCE; PHOSPHORYLATION;
D O I
10.3390/ijms160922976
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Colorectal cancer (CRC) is a heterogeneous disease with multiple underlying causative genetic mutations. Genetic mutations in the phosphatidylinositol-3 kinase (PI3K) and the mitogen activated protein kinase (MAPK) pathways are frequently implicated in CRC. Targeting the downstream substrate MEK in these mutated tumors stands out as a potential target in CRC. Several selective inhibitors of MEK have entered clinical trial evaluation; however, clinical activity with single MEK inhibitors has been rarely observed and acquired resistance seems to be inevitable. Amplification of the driving oncogene KRAS(13D), which increases signaling through the ERK1/2 pathway, upregulation of the noncanonical wingless/calcium signaling pathway (Wnt), and coexisting PIK3CA mutations have all been implicated with resistance against MEK inhibitor therapy in KRAS mutated CRC. The Wnt pathway and amplification of the oncogene have also been associated with resistance to MEK inhibitors in CRCs harboring BRAF mutations. Thus, dual targeted inhibition of MEK and PI3K pathway effectors (mTOR, PI3K, AKT, IGF-1R or PI3K/mTOR inhibitors) presents a potential strategy to overcome resistance to MEK inhibitor therapy. Many clinical trials are underway to evaluate multiple combinations of these pathway inhibitors in solid tumors.
引用
收藏
页码:22976 / 22988
页数:13
相关论文
共 50 条
  • [41] Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer
    Roper, Jatin
    Sinnamon, Mark J.
    Coffee, Erin M.
    Belmont, Peter
    Keung, Lily
    Georgeon-Richard, Larissa
    Wang, Wei Vivian
    Faber, Anthony C.
    Yun, Jihye
    Yilmaz, Oemer H.
    Bronson, Roderick T.
    Martin, Eric S.
    Tsichlis, Philip N.
    Hung, Kenneth E.
    CANCER LETTERS, 2014, 347 (02) : 204 - 211
  • [42] Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer
    Kim, Areumnuri
    Lee, Jung-Eun
    Lee, Seung-Sook
    Kim, Cherin
    Lee, Sun-Joo
    Jang, Won-Suk
    Park, Sunhoo
    INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (04) : 984 - 996
  • [43] Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ
    Schwartz, Sarit
    Wongvipat, John
    Trigwell, Cath B.
    Hancox, Urs
    Carver, Brett S.
    Rodrik-Outmezguine, Vanessa
    Will, Marie
    Yellen, Paige
    de Stanchina, Elisa
    Baselga, Jose
    Scher, Howard I.
    Barry, Simon T.
    Sawyers, Charles L.
    Chandarlapaty, Sarat
    Rosen, Neal
    CANCER CELL, 2015, 27 (01) : 109 - 122
  • [44] Selective Eradication of Colon Cancer Cells Harboring PI3K and/or MAPK Pathway Mutations in 3D Culture by Combined PI3K/AKT/mTOR Pathway and MEK Inhibition
    Atanasova, Velina S.
    Riedl, Angelika
    Strobl, Marcus
    Flandorfer, Julia
    Unterleuthner, Daniela
    Weindorfer, Claudia
    Neuhold, Patrick
    Stang, Simone
    Hengstschlaeger, Markus
    Bergmann, Michael
    Dolznig, Helmut
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (02)
  • [45] Portrait of the PI3K/AKT pathway in colorectal cancer
    Danielsen, Stine Aske
    Eide, Peter Wold
    Nesbakken, Arild
    Guren, Tormod
    Leithe, Edward
    Lothe, Ragnhild A.
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2015, 1855 (01): : 104 - 121
  • [46] EGFR and Downstream Genetic Alterations in KRAS/BRAF and PI3K/AKT Pathways in Colorectal Cancer - Implications for Targeted Therapy
    Berg, Marianne
    Soreide, Kjetil
    DISCOVERY MEDICINE, 2012, 14 (76) : 207 - 214
  • [47] Resistance to BRAF inhibition in BRAF V600E colorectal cancer is associated with PI3K/AKT activation and hypermethylation
    Mao, Muling
    Tsao, Lawrence
    Dayyani, Farshid
    Nanda, Vashisht Gopal Yennu
    Mills, Gordon
    Bollag, Gideon
    Davies, Michael
    Gallick, Gary
    Kopetz, Scott
    CANCER RESEARCH, 2011, 71
  • [48] Ocular Toxicity Profile of Novel PI3K/MEK Dual Inhibitor
    Smith, Andrew
    Pawar, Mercy D.
    Besirli, Cagri G.
    Van Dort, Marcian E.
    Ross, Brian D.
    Galban, Stefanie
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [49] The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
    E J Haagensen
    S Kyle
    G S Beale
    R J Maxwell
    D R Newell
    British Journal of Cancer, 2012, 106 : 1386 - 1394
  • [50] The Genomic Environment of BRAF Mutated and BRAF/PIK3CA Double Mutated Colorectal Cancers
    Voutsadakis, Ioannis A.
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (17)